OTC Nasal Spray Manufacturing Controls That Prevent FDA Recalls

When a saline nasal spray ends up on FDA's recall list, the product failure is almost never the real story. The real story is a quality system that didn't catch a problem in time — or a third-party manufacturer relationship that wasn't managed tightly enough to surface one.

On June 11, 2026, Beekeeper's Naturals announced a voluntary nationwide recall of its Saline Nasal Spray (lot #5950, Exp. 02/2028), sold through Amazon, after lot testing results exceeded acceptable limits. The product was manufactured at a third-party facility. FDA's recall notice is publicly available here.

I want to be clear about what this article is and isn't. It's not a commentary on Beekeeper's Naturals — a voluntary recall, self-initiated, is actually the system working. What I want to walk through is the class of quality system failures that produce this outcome in the first place, because this situation is far more common than people realize and almost entirely preventable with the right controls in place.

Why Nasal Sprays Carry Higher Compliance Risk Than Most OTC Products

Nasal drug and nasal cosmetic/device products sit in a unique regulatory space. Depending on how the product is labeled and what it claims to do, a saline nasal spray may be regulated as a drug under 21 CFR Part 211 (Current Good Manufacturing Practice for finished pharmaceuticals), as a device, or as a cosmetic under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). That ambiguity alone creates compliance exposure.

What's consistent across all three pathways is this: nasal products contact mucous membranes, which means microbial contamination, bioburden, and preservative efficacy are not theoretical concerns — they're safety concerns with direct patient impact. FDA's guidance on Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products (published May 2002, with ongoing enforcement emphasis) makes clear that manufacturers must demonstrate microbial quality at every stage of production, not just at release.

According to FDA's database, device and drug recalls related to microbial or sterility failures represent a consistent share of Class II recall actions year over year. A single lot failure at a contract manufacturer, if not caught at the right control point, can move from facility floor to consumer in weeks.

What "Tested Above Acceptable Limits" Actually Means

The Beekeeper's Naturals recall notice states that lot #5950 "tested above our acceptable limits." That phrase is doing a lot of work, and it's worth unpacking.

In regulated manufacturing, acceptable limits for microbial content in non-sterile drug products are typically defined by the United States Pharmacopeia (USP) — specifically USP <61> (Microbial Examination of Nonsterile Products: Microbial Enumeration Tests) and USP <62> (Tests for Specified Microorganisms). For nasal products, even those not formally classified as sterile preparations, these limits are tight because of the route of administration.

Exceeding those limits means one of several things happened upstream:

• Raw material inputs carried elevated bioburden that wasn't detected at incoming inspection
• Water system quality (purified water or water for injection, depending on product classification) was out of specification during a production run
• Environmental monitoring in the manufacturing suite failed to catch a contamination event
• The preservative system was inadequate or not validated to perform across the product's shelf life
• Testing at release was not conducted, was conducted incorrectly, or results were not reviewed against defined limits before distribution

Any one of these is a quality system gap. In my experience reviewing manufacturing agreements and quality systems for regulated products, it's rarely just one — it's usually a combination of gaps that compound each other quietly until a lot test result makes the problem visible.

The Third-Party Manufacturer Problem Is the Real Lesson Here

The Beekeeper's Naturals notice specifically notes the product was "produced at a third-party manufacturer." This detail matters enormously, and it's where I think the most useful prevention guidance lives.

Brand owners who outsource manufacturing — and most OTC supplement and personal care brands do — often underestimate what they're actually taking on. When you put your name on a product, FDA holds you responsible for its compliance, regardless of who made it. 21 CFR 211.22 is explicit: the quality control unit's responsibilities don't transfer to your CMO just because you signed a manufacturing agreement.

Here's what a quality agreement with a contract manufacturer (CMO) should require but frequently doesn't:

The gap between what quality agreements say and what brand owners actually do with their CMO relationships is wide. In my work with clients across the dietary supplement and OTC drug space, I'd say the majority of brands receiving finished goods from CMOs have never conducted an on-site audit of that facility. That's not a criticism — it's just the reality of how small and mid-size brands operate. But it is a gap, and it's exactly the gap that produces recall events.

The Quality Systems That Would Have Prevented This

Let me be specific about the controls that, if properly implemented, catch this type of issue before a lot ships.

Validated Release Testing Protocol

A validated release testing protocol means you have a written procedure specifying which tests are run on every lot, what the acceptance criteria are, who reviews the results, and what happens when a result is out of specification. For a nasal spray, that procedure should include microbial enumeration and specified organism testing at minimum.

"Validated" is doing real work in that sentence. It's not enough to run a test. The test method itself needs to be validated per USP <1223> (Validation of Microbial Recovery from Pharmacopeial Articles) to confirm it performs accurately in your specific product matrix. Some nasal spray formulations contain preservatives or other antimicrobial ingredients that can suppress microbial growth in test media and produce a false-passing result. If your method hasn't been validated against your actual formula, your release test results are not reliable.

Supplier Qualification Program

21 CFR 211.84 requires testing or examination of incoming drug product components, and FDA's draft guidance on Contract Manufacturing Arrangements for Drugs (2016) reinforces that brand owners bear ultimate responsibility for supplier and CMO qualification. A functional supplier qualification program has three moving parts:

1. Initial qualification — audit, document review, or survey before you begin purchasing
2. Ongoing qualification — periodic re-audit and review of trend data, with defined triggers for re-qualification
3. Change notification requirements — contractual obligations for your CMO to notify you of supplier changes, equipment changes, or facility changes that could affect your product

The third one is where things quietly break down. A CMO changes their water system supplier, or switches to a different raw material vendor for cost reasons, and the brand owner never finds out. The product looks the same. The COAs look similar. And then a lot test comes back out of specification.

Annual Product Quality Reviews

21 CFR 211.180(e) requires annual product reviews for drug products — and even brands operating under cosmetic or supplement frameworks benefit from running a similar process. An annual review asks: across all lots produced this year, what does the data tell us? Are microbial results trending toward a limit? Are there clusters of deviations at certain CMO facilities or during certain production windows?

Trend analysis is how you catch a developing problem before it becomes a recall. A single lot that tests slightly elevated is a data point. Three lots over six months showing a gradual trend is a signal. The annual review is the process that makes that signal visible to decision-makers before FDA makes it visible to the public.

What MoCRA Changes for Cosmetic Nasal Products (Effective Now)

If your nasal spray is regulated as a cosmetic — no drug claims, no active drug ingredients — the Modernization of Cosmetics Regulation Act of 2022 changed your compliance landscape in ways that are directly relevant here.

Facility registration and product listing requirements under MoCRA became effective December 29, 2023 for large manufacturers and July 1, 2024 for small businesses. But the provision with the most immediate practical impact for quality systems is FDA's new authority under 21 USC 364d to require a "responsible person" to conduct safety substantiation and maintain records substantiating that the cosmetic is safe.

For a nasal spray cosmetic, safety substantiation that would satisfy FDA scrutiny should include:

• Microbial testing data per USP <61>/<62> or equivalent
• Preservative efficacy testing per USP <51>
• Stability data confirming microbial quality at the end of labeled shelf life
• Challenge testing data if the product makes any implicit safety claim

The practical deadline for getting these records in order is now — FDA inspections of cosmetic facilities are actively occurring, and the framework for what "adequate safety substantiation" looks like is still being refined through enforcement actions. Waiting for more guidance before acting is a gamble I wouldn't recommend.

Amazon as a Distribution Channel Creates Specific Compliance Pressure

One detail in the Beekeeper's Naturals recall that I think deserves more attention: this lot was sold exclusively through Amazon. That's a distribution model that introduces some specific quality considerations.

Amazon's fulfillment model means that once a product enters an FBA (Fulfilled by Amazon) warehouse, the seller has limited visibility into inventory rotation, storage conditions, and lot traceability at the unit level. For a product with microbial quality concerns, this matters. The recall notice covers lot #5950 only — which suggests lot segregation was possible — but effective lot traceability through a marketplace fulfillment model requires deliberate system design on the seller's side, not just an assumption that lot numbers will flow cleanly through Amazon's systems.

For brands selling health and wellness products through Amazon or similar marketplace channels, I'd add these to the standard quality system requirements:

• Lot-level traceability documentation maintained internally, independent of marketplace systems
• Clear written procedures for initiating a recall or market withdrawal through marketplace channels, tested at least annually
• Defined communication templates for Amazon seller support, customer notification, and FDA MedWatch reporting

Practical Compliance Guidance: Where to Start

If you're a brand owner, quality director, or regulatory lead for an OTC drug, cosmetic, or dietary supplement with any nasal or topical delivery format, here's the honest prioritization:

Immediate (within 30 days): - Pull your most recent lot test results for all nasal or topical products and confirm acceptance criteria are defined in writing - Review your quality agreement with each CMO and confirm it includes audit rights, deviation notification timelines, and release testing data sharing - Confirm your finished product release testing method has been validated for your specific product matrix

Near-term (within 90 days): - Schedule or commission a CMO audit for any facility producing nasal, ophthalmic, or mucosal-contact products - Confirm your annual product quality review process is documented and that microbial trend data is part of the review - If your product is a cosmetic under MoCRA, confirm facility registration and product listing are complete and up to date

Ongoing: - Build preservative efficacy revalidation triggers into your change control process — any formula change, supplier change, or packaging change should prompt reassessment - Review water system qualification records from your CMO at least annually as part of your supplier management process

The Broader Pattern Worth Noticing

Voluntary recalls of the kind Beekeeper's Naturals initiated are not the failure of the system — they're actually the quality system doing what it's supposed to do, catching a problem and removing product from commerce. The failure mode to prevent is the one where the problem doesn't get caught, where a consumer uses a contaminated nasal spray and no one finds out until there's an adverse event report.

The distance between those two outcomes is almost entirely determined by the quality infrastructure a brand has built before a problem appears. Good release testing. Real CMO oversight. Meaningful annual reviews. Those aren't bureaucratic overhead — they're what makes the difference between a voluntary recall and something worse.

If you're not sure where your quality system has gaps, that's a solvable problem. Certify Consulting works with OTC brands and supplement manufacturers to build or audit quality systems before FDA finds the gaps first. With 200+ clients and a 100% first-time audit pass rate, the pattern of what works — and what doesn't — is reasonably clear to me by now.

You can also explore our FDA compliance resources for additional guidance on CMO qualification and OTC drug GMP requirements.

Last updated: 2026-06-28